Latest news with #ZynextVentures
Cision Canada
5 days ago
- Business
- Cision Canada
Zynext Ventures acquires stake in Agenus, expands its immuno-oncology pipeline and global reach
Enables Agenus to accelerate development of its lead BOT/BAL programme and strategically expand into high-unmet need indications and earlier lines of treatment. The investment underscores Zynext Ventures' commitment to advancing innovation in critical therapeutic areas. PENNINGTON, N.J., June 3, 2025 /CNW/ -- Zynext Ventures USA LLC (Zynext), the venture capital arm of Zydus Lifesciences (Zydus), today announced its investment in Agenus Inc., a leading US-based immuno-oncology company developing next-generation therapeutics for high-unmet need cancers. Agenus' lead programme comprising Botensilimab (BOT) and Balstilimab (BAL), is a next-generation immunotherapy platform designed to strengthen and sustain the immune system's response against tumour cells. Currently in advanced clinical trials, BOT/BAL have demonstrated significant clinical activity across nine cancer types in more than 1,200 patients, including both late-stage and neoadjuvant settings. "Our investment in Agenus aligns perfectly with our vision to advance life-changing therapies and offer novel solutions anchored on science, innovation and health to empower patients," said Dr. Sharvil Patel, Managing Director of Zydus Lifesciences. "Our extensive global partner network will also play a key role in supporting Agenus' entry into new indications and geographies, allowing these innovative therapies to reach more patients, faster. This collaboration will help propel Agenus' programmes and unlock their full potential." In addition to capital, Zynext Ventures will bring deep expertise in data analytics and access to a broad global network of biotech, regulatory, and clinical partners. This synergistic approach aims to unlock new avenues for Agenus, enabling the company to broaden the application of its BOT/BAL programme into earlier lines of treatment and address a wider spectrum of cancers with significant unmet medical needs. Dr. Garo Armen, Chairman and CEO of Agenus, said, "We are delighted to partner with Zynext Ventures in a truly synergistic relationship. BOT/BAL's remarkable results across nine distinct cancers, in both late-stage and neoadjuvant settings, inspire us to push the boundaries of what is possible in oncology. Zydus' commercial reach and expertise make them an ideal partner to accelerate the delivery of this potentially transformative therapy." About Zynext Ventures Zynext Ventures is the investment arm of Zydus Lifesciences. The venture capital firm focuses on identifying and investing in promising early-stage and growth-stage companies in the healthcare sector. Zynext Ventures provides financial support, strategic guidance, and industry expertise to its portfolio companies, helping them achieve their full potential and make a meaningful impact on the lives of patients. About Zydus Zydus Lifesciences Ltd. with an overarching purpose of empowering people with freedom to live healthier and more fulfilled lives, is an innovative, global lifesciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies. The group employs 27,000 people worldwide, including 1,400 scientists engaged in R & D, and is driven by its mission to unlock new possibilities in lifesciences through quality healthcare solutions that impact lives. The group aspires to transform lives through path-breaking discoveries. Over the last decade, Zydus has introduced several innovative, first-in-class products in the market for treating unmet healthcare needs with vaccines, therapeutics, biologicals and biosimilars. For more details visit: LinkedIn: @Zydusuniverse Instagram: @ZydusUniverse About Agenus Agenus Inc. is a clinical-stage immuno-oncology company committed to developing immune therapies that effectively combat cancer. Leveraging proprietary scientific platforms, the company's pipeline includes multiple checkpoint antibody candidates, vaccines, and cell therapies. Headquartered in Lexington, MA, Agenus operates globally, driving innovations to bring better cancer treatments to patients. For more details visit: Forward-Looking Statements This press release contains forward-looking statements regarding the planned collaboration, the development and commercialization of BOT/BAL, and anticipated timelines. Actual results may differ due to various risks and uncertainties, including regulatory approvals and other factors. Readers are encouraged to review each company's public filings for additional information regarding potential risks and timelines.
Yahoo
5 days ago
- Business
- Yahoo
Zynext Ventures acquires stake in Agenus, expands its immuno-oncology pipeline and global reach
Enables Agenus to accelerate development of its lead BOT/BAL programme and strategically expand into high-unmet need indications and earlier lines of treatment. The investment underscores Zynext Ventures' commitment to advancing innovation in critical therapeutic areas. PENNINGTON, N.J., June 3, 2025 /CNW/ -- Zynext Ventures USA LLC (Zynext), the venture capital arm of Zydus Lifesciences (Zydus), today announced its investment in Agenus Inc., a leading US-based immuno-oncology company developing next-generation therapeutics for high-unmet need cancers. Agenus' lead programme comprising Botensilimab (BOT) and Balstilimab (BAL), is a next-generation immunotherapy platform designed to strengthen and sustain the immune system's response against tumour cells. Currently in advanced clinical trials, BOT/BAL have demonstrated significant clinical activity across nine cancer types in more than 1,200 patients, including both late-stage and neoadjuvant settings. "Our investment in Agenus aligns perfectly with our vision to advance life-changing therapies and offer novel solutions anchored on science, innovation and health to empower patients," said Dr. Sharvil Patel, Managing Director of Zydus Lifesciences. "Our extensive global partner network will also play a key role in supporting Agenus' entry into new indications and geographies, allowing these innovative therapies to reach more patients, faster. This collaboration will help propel Agenus' programmes and unlock their full potential." In addition to capital, Zynext Ventures will bring deep expertise in data analytics and access to a broad global network of biotech, regulatory, and clinical partners. This synergistic approach aims to unlock new avenues for Agenus, enabling the company to broaden the application of its BOT/BAL programme into earlier lines of treatment and address a wider spectrum of cancers with significant unmet medical needs. Dr. Garo Armen, Chairman and CEO of Agenus, said, "We are delighted to partner with Zynext Ventures in a truly synergistic relationship. BOT/BAL's remarkable results across nine distinct cancers, in both late-stage and neoadjuvant settings, inspire us to push the boundaries of what is possible in oncology. Zydus' commercial reach and expertise make them an ideal partner to accelerate the delivery of this potentially transformative therapy." About Zynext Ventures Zynext Ventures is the investment arm of Zydus Lifesciences. The venture capital firm focuses on identifying and investing in promising early-stage and growth-stage companies in the healthcare sector. Zynext Ventures provides financial support, strategic guidance, and industry expertise to its portfolio companies, helping them achieve their full potential and make a meaningful impact on the lives of patients. For more details visit: LinkedIn: Zynext Ventures Twitter: @ZynextVentures About Zydus Zydus Lifesciences Ltd. with an overarching purpose of empowering people with freedom to live healthier and more fulfilled lives, is an innovative, global lifesciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies. The group employs 27,000 people worldwide, including 1,400 scientists engaged in R & D, and is driven by its mission to unlock new possibilities in lifesciences through quality healthcare solutions that impact lives. The group aspires to transform lives through path-breaking discoveries. Over the last decade, Zydus has introduced several innovative, first-in-class products in the market for treating unmet healthcare needs with vaccines, therapeutics, biologicals and biosimilars. For more details visit: LinkedIn: @Zydusuniverse Instagram: @ZydusUniverse About Agenus Agenus Inc. is a clinical-stage immuno-oncology company committed to developing immune therapies that effectively combat cancer. Leveraging proprietary scientific platforms, the company's pipeline includes multiple checkpoint antibody candidates, vaccines, and cell therapies. Headquartered in Lexington, MA, Agenus operates globally, driving innovations to bring better cancer treatments to patients. For more details visit: Forward-Looking Statements This press release contains forward-looking statements regarding the planned collaboration, the development and commercialization of BOT/BAL, and anticipated timelines. Actual results may differ due to various risks and uncertainties, including regulatory approvals and other factors. Readers are encouraged to review each company's public filings for additional information regarding potential risks and timelines. Logo: View original content: SOURCE Zynext Ventures View original content:
Globe and Mail
16-04-2025
- Business
- Globe and Mail
Zynext Ventures Invests in Feldan Therapeutics to Drive Innovation in Intracellular Drug Delivery
PENNINGTON, N.J. and QUÉBEC , April 16, 2025 /CNW/ -- Zynext Ventures USA LLC (Zynext Ventures), the venture capital arm of Zydus Lifesciences (Zydus), today announced its investment in Feldan Therapeutics (Feldan), a Canada -based early clinical-stage pharmaceutical company pioneering the development of treatments based on intracellular delivery of therapeutics. Feldan's proprietary Shuttle peptide technology enables the efficient and targeted delivery of biomolecules into cells, unlocking new therapeutic possibilities. The company's lead candidate, FLD-103, is administered directly into basal cell carcinoma (BCC) lesions, where the Shuttle peptide facilitates the delivery of a Hedgehog inhibitor to its target within BCC cells. This innovative approach aims to provide BCC patients with a non-surgical treatment option that improves outcomes and significantly enhances their quality of life. Additionally, Feldan is advancing a pulmonary program that leverages the Shuttle's unique ability to transport biomolecules into hard-to-deliver lung cells to address the unmet and growing medical needs of patients with respiratory diseases. Speaking on the development, Dr. Sharvil Patel, MD of Zydus Lifesciences, said, "At Zydus, we are committed towards advancing the development of novel therapeutics to addressing critical gaps in healthcare through innovation. We are pleased to support Feldan in exploring a potentially safe and targeted option for patients with dermatological and pulmonary disease and help them lead a better quality of life." Jay Kothari , Director of Zynext Ventures, highlighted, "Feldan's platform has the potential to transform intracellular delivery and pioneer next-generation therapeutics, aligning with the disruptive innovations we aim to add to our portfolio." "This partnership with Zynext Ventures marks an exciting step forward in our commitment to improve patients' quality of life and address critical drug delivery challenges," said François- Thomas Michaud , CEO of Feldan Therapeutics. "With Zynext Ventures' strategic expertise and shared dedication to innovation, we are well-positioned to accelerate the development of next-generation therapies." About Zynext Ventures Zynext Ventures is the investment arm of Zydus Lifesciences. The venture capital firm focuses on identifying and investing in promising early-stage and growth-stage companies in the healthcare sector. Zynext Ventures provides financial support, strategic guidance, and industry expertise to its portfolio companies, helping them achieve their full potential and make a meaningful impact on the lives of patients. For more details visit: About Zydus Zydus Lifesciences Ltd. with an overarching purpose of empowering people with freedom to live healthier and more fulfilled lives, is an innovative, global lifesciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies. The group employs 27,000 people worldwide, including 1,400 scientists engaged in R & D, and is driven by its mission to unlock new possibilities in lifesciences through quality healthcare solutions that impact lives. The group aspires to transform lives through path-breaking discoveries. Over the last decade, Zydus has introduced several innovative, first-in-class products in the market for treating unmet healthcare needs with vaccines, therapeutics, biologicals and biosimilars. For more details visit: About Feldan Feldan is a clinical-stage pharmaceutical company specializing in the development of treatments based on the intracellular delivery of therapeutics. Its proprietary peptide-based technology, the Feldan Shuttle, enables the safe and efficient delivery of antisense oligonucleotides into cells, unlocking the potential for a new generation of therapies. Feldan's lead product for BCC (FLD-103) is in a Phase 1/2a clinical trial, and the company's pipeline expansion is focused on skin and lung diseases. SOURCE Zydus Lifesciences Ltd
Yahoo
16-04-2025
- Business
- Yahoo
Zynext Ventures Invests in Feldan Therapeutics to Drive Innovation in Intracellular Drug Delivery
PENNINGTON, N.J. and QUÉBEC, April 16, 2025 /CNW/ -- Zynext Ventures USA LLC (Zynext Ventures), the venture capital arm of Zydus Lifesciences (Zydus), today announced its investment in Feldan Therapeutics (Feldan), a Canada-based early clinical-stage pharmaceutical company pioneering the development of treatments based on intracellular delivery of therapeutics. Feldan's proprietary Shuttle peptide technology enables the efficient and targeted delivery of biomolecules into cells, unlocking new therapeutic possibilities. The company's lead candidate, FLD-103, is administered directly into basal cell carcinoma (BCC) lesions, where the Shuttle peptide facilitates the delivery of a Hedgehog inhibitor to its target within BCC cells. This innovative approach aims to provide BCC patients with a non-surgical treatment option that improves outcomes and significantly enhances their quality of life. Additionally, Feldan is advancing a pulmonary program that leverages the Shuttle's unique ability to transport biomolecules into hard-to-deliver lung cells to address the unmet and growing medical needs of patients with respiratory diseases. Speaking on the development, Dr. Sharvil Patel, MD of Zydus Lifesciences, said, "At Zydus, we are committed towards advancing the development of novel therapeutics to addressing critical gaps in healthcare through innovation. We are pleased to support Feldan in exploring a potentially safe and targeted option for patients with dermatological and pulmonary disease and help them lead a better quality of life." Jay Kothari, Director of Zynext Ventures, highlighted, "Feldan's platform has the potential to transform intracellular delivery and pioneer next-generation therapeutics, aligning with the disruptive innovations we aim to add to our portfolio." "This partnership with Zynext Ventures marks an exciting step forward in our commitment to improve patients' quality of life and address critical drug delivery challenges," said François-Thomas Michaud, CEO of Feldan Therapeutics. "With Zynext Ventures' strategic expertise and shared dedication to innovation, we are well-positioned to accelerate the development of next-generation therapies." About Zynext Ventures Zynext Ventures is the investment arm of Zydus Lifesciences. The venture capital firm focuses on identifying and investing in promising early-stage and growth-stage companies in the healthcare sector. Zynext Ventures provides financial support, strategic guidance, and industry expertise to its portfolio companies, helping them achieve their full potential and make a meaningful impact on the lives of patients. For more details visit: LinkedIn: Zynext VenturesTwitter: @ZynextVentures About Zydus Zydus Lifesciences Ltd. with an overarching purpose of empowering people with freedom to live healthier and more fulfilled lives, is an innovative, global lifesciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies. The group employs 27,000 people worldwide, including 1,400 scientists engaged in R & D, and is driven by its mission to unlock new possibilities in lifesciences through quality healthcare solutions that impact lives. The group aspires to transform lives through path-breaking discoveries. Over the last decade, Zydus has introduced several innovative, first-in-class products in the market for treating unmet healthcare needs with vaccines, therapeutics, biologicals and biosimilars. For more details visit: About Feldan Feldan is a clinical-stage pharmaceutical company specializing in the development of treatments based on the intracellular delivery of therapeutics. Its proprietary peptide-based technology, the Feldan Shuttle, enables the safe and efficient delivery of antisense oligonucleotides into cells, unlocking the potential for a new generation of therapies. Feldan's lead product for BCC (FLD-103) is in a Phase 1/2a clinical trial, and the company's pipeline expansion is focused on skin and lung diseases. For more details visit: Feldan Therapeutics Logo - View original content: SOURCE Zydus Lifesciences Ltd View original content: Sign in to access your portfolio
Yahoo
12-03-2025
- Business
- Yahoo
Zynext Ventures invests in Illexcor Therapeutics to advance novel oral therapy for sickle cell disease
PENNINGTON, N.J., March 12, 2025 /CNW/ -- Zynext Ventures USA LLC (Zynext Ventures), the venture capital arm of Zydus Lifesciences (Zydus), today announced its investment in Illexcor Therapeutics (Illexcor), a pioneering biopharmaceutical company developing next-generation oral therapies for sickle cell disease (SCD). This investment underscores Zynext Ventures' commitment to supporting disruptive healthcare innovations that address significant unmet medical needs. Illexcor is developing a first-in-class oral drug that directly targets the root cause of SCD. Their lead asset, currently in preclinical development, is designed to bind to Hemoglobin S and effectively block polymerization and sickling, offering the potential for disease-modifying clinical benefits. Speaking on the development, Dr. Sharvil Patel, MD of Zydus Lifesciences, said, "This investment reflects our commitment to patients battling rare and orphan diseases. Recognizing the profound impact of sickle cell disease on patients' lives, we are pleased to support Illexcor in their efforts to develop a novel therapeutic solution addressing this critical unmet medical need." Emphasizing the strategic significance of the investment, Jay Kothari, Director of Zynext Ventures said, "This investment is consistent with Zynext Ventures' objective of identifying and fostering transformative early-stage healthcare innovations. Beyond the financial backing, Zynext Ventures will leverage its unique data analytics and strategic expertise to accelerate Illexcor's path to delivering this potentially life-changing therapy globally." Andrew Fleischman, CEO of Illexcor stated, "We are excited to partner with Zynext Ventures to advance our lead drug ILX002 into clinical trials later this year. We are hopeful that ILX002 will be a transformative treatment not only for SCD patients in the U.S. but also for millions around the globe. Zynext Ventures and Zydus Lifesciences are in a strategic position to help us achieve these goals." Sickle cell disease is a devastating and debilitating genetic condition that affects up to 10 million people worldwide. The disease continues to severely impact quality of life and longevity. Highly efficacious oral drug therapies are urgently needed to manage this condition on a global scale. About Zynext Ventures Zynext Ventures is the investment arm of Zydus Lifesciences. The venture capital firm focuses on identifying and investing in promising early-stage and growth-stage companies in the healthcare sector. Zynext Ventures provides financial support, strategic guidance, and industry expertise to its portfolio companies, helping them achieve their full potential and make a meaningful impact on the lives of patients. To learn more about Zynext Ventures, please visit: LinkedIn: Zynext Ventures Twitter: @ZynextVentures About Zydus Zydus Lifesciences Ltd. with an overarching purpose of empowering people with freedom to live healthier and more fulfilled lives, is an innovative, global lifesciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies. The group employs 27,000 people worldwide, including 1,400 scientists engaged in R & D, and is driven by its mission to unlock new possibilities in lifesciences through quality healthcare solutions that impact lives. The group aspires to transform lives through path-breaking discoveries. Over the last decade, Zydus has introduced several innovative, first-in-class products in the market for treating unmet healthcare needs with vaccines, therapeutics, biologicals and biosimilars. For more details visit About Illexcor Illexcor Therapeutics is a biopharmaceutical company focused on the discovery and development of innovative oral therapies for sickle cell disease. Their lead asset is a first-in-class drug designed to directly target the root cause of SCD, offering the potential for significant disease-modifying clinical benefits. Logo - View original content to download multimedia: SOURCE Zydus View original content to download multimedia: Sign in to access your portfolio
